Gemcitabine 200mg 1’s Vial

Indications of gemcitabine:

• Non-small cell lung cancer (NSCLC)
• Pancreatic cancer
• Breast cancer
• Ovarian cancer
• Bladder cancer
• May be used in combination with other chemotherapy medicines depending on the treatment plan.

Administration:

• Supplied as a powder for solution to be dissolved in sterile saline.
• Administered by intravenous infusion (usually over 30 minutes) in a hospital or oncology unit.
• Dosage is determined by the patient’s body surface area, type of cancer, and treatment schedule.
• Typically given in treatment cycles with rest periods in between.

Safety Information:

• Do not use in patients with known hypersensitivity to gemcitabine or those with severe bone marrow suppression.
• Use with caution in patients with liver, kidney, or lung problems, or those who have had recent radiotherapy.
• Common side effects: nausea, vomiting, fever, flu-like symptoms, rash, fatigue, mild hair loss.
• Serious risks: low blood cell counts (anemia, neutropenia, thrombocytopenia), increased infection risk, bleeding, liver toxicity, kidney impairment, and rare lung complications.
• Requires regular monitoring of blood counts, kidney, and liver function during treatment.

Notice:
Gemcitabine 200mg Vial is a prescription-only chemotherapy medicine. It must be prepared and administered by trained oncology healthcare professionals in a controlled hospital setting.